Abstract
The considerable mortality and morbidity associated with atrial fibrillation (AF) pose a substantial burden on patients and health care services. Although the management of AF historically focused on decreasing AF recurrence, it evolved over time in favor of rate control. Recently, more emphasis has been placed on reducing adverse cardiovascular outcomes using rhythm control, generally by using safe and effective rhythm-control therapies (typically antiarrhythmic drugs and/or AF ablation). Evidence increasingly supports early rhythm control in patients with AF that has not become long-standing, but current clinical practice and guidelines do not yet fully reflect this change. Early rhythm control may effectively reduce irreversible atrial remodeling and prevent AF-related deaths, heart failure, and strokes in high-risk patients. It has the potential to halt progression and potentially save patients from years of symptomatic AF; therefore, it should be offered more widely.
Original language | English |
---|---|
Pages (from-to) | 1932-1948 |
Number of pages | 17 |
Journal | Journal of the American College of Cardiology |
Volume | 79 |
Issue number | 19 |
DOIs | |
Publication status | Published - 17 May 2022 |
Keywords
- Anti-Arrhythmia Agents/therapeutic use
- Atrial Fibrillation/drug therapy
- Atrial Remodeling
- Catheter Ablation/adverse effects
- Humans
- Stroke/etiology
- Treatment Outcome
- 1ST-LINE TREATMENT
- RHYTHM CONTROL TREATMENT
- early intervention
- paroxysmal atrial fibrillation
- SURGICAL ABLATION
- catheter ablation
- PULMONARY-VEIN ABLATION
- ANTIARRHYTHMIC-DRUG THERAPY
- atrial fibrillation progression
- EXPERT CONSENSUS STATEMENT
- 2010 ESC GUIDELINES
- new-onset atrial fibrillation
- CATHETER ABLATION
- antiarrhythmic drugs
- RADIOFREQUENCY ABLATION
- SINUS RHYTHM